NCT00271492View on ClinicalTrials.gov

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

June 30, 2006

Study Completion Date

January 31, 2008

Conditions
Endothelial Dysfunction
Interventions
DRUG

Atrasentan

1 10mg capsule to be taken daily for 6 month study period.

DRUG

Atrasentan

1 10mg capsule per day for the 6 month study period.

DRUG

atrasentan

One 10 mg capsule per day for 6 month study period

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Mayo Clinic

OTHER